Survodutide // The Glucagon Edge
Boehringer Ingelheim's dual GLP-1/glucagon receptor agonist — the compound that isolates the glucagon advantage without GIP. Phase 3 trials show ~19% weight loss, with particular promise for NASH (fatty liver disease) where glucagon-driven hepatic fat oxidation addresses the root pathology. If retatrutide is the triple threat, survodutide is the focused two-punch.
Two receptors. Liver-focused.
Where tirzepatide pairs GLP-1 with GIP (targeting adipose tissue), survodutide pairs GLP-1 with glucagon (targeting the liver). This is a fundamentally different metabolic strategy — glucagon drives hepatic fat oxidation and increases energy expenditure, making survodutide the most liver-focused weight loss compound in development.
Weekly injection with titration.
Survodutide follows a GLP-1 class titration protocol with weekly subcutaneous injections. Dose escalation is slower due to the glucagon component's effects on blood sugar and hepatic metabolism. Phase 3 data will establish the final dosing schedule.
SYNCHRONIZE — the NASH and obesity dual play.
Survodutide's development is driven by two parallel indications: obesity and NASH. Phase 2 data showed approximately 19% body weight loss — competitive but slightly behind tirzepatide and retatrutide. However, the NASH data is where survodutide stands apart: significant reductions in liver fat content and improvements in fibrosis markers that exceed what GLP-1-only compounds achieve.
The SYNCHRONIZE Phase 3 program (Boehringer Ingelheim) is investigating both weight loss and liver outcomes. If the NASH data holds, survodutide could become the first approved treatment that addresses both obesity and fatty liver disease simultaneously. The glucagon receptor activation drives hepatic fat clearance in a way that GIP-based compounds (tirzepatide) and amylin-based compounds (CagriSema) cannot match.
How it stacks against the competition.
| Compound | Receptors | Weight Loss | Half-Life | FDA Status |
|---|---|---|---|---|
| Semaglutide | GLP-1 | ~15–17% | ~7 days | Approved (Wegovy) |
| Tirzepatide | GLP-1 + GIP | ~20–26% | ~5 days | Approved (Zepbound) |
| Survodutide | GLP-1 + GCGR | ~19% | ~4 days | Phase 3 Trial |
| Retatrutide | GLP-1 + GIP + GCGR | ~24% | ~6 days | Phase 3 Trial |
| CagriSema | GLP-1 + Amylin | ~22.7% | ~7 days | Phase 3 Trial |
What to watch for.
Survodutide's side effect profile requires careful monitoring. The glucagon component introduces unique monitoring needs around blood glucose and hepatic function that pure GLP-1 agonists don't require.
- GI effects consistent with GLP-1 class (nausea, diarrhea, constipation)
- Decreased appetite (therapeutic effect)
- Potential blood glucose fluctuations (glucagon component)
- Injection site reactions
- Hepatic enzyme changes (monitor — glucagon activates liver metabolism)
- Safety profile still being characterized in Phase 3
- Weight loss slightly below tirzepatide/retatrutide levels
- Long-term data accumulating
- HbA1c and fasting glucose (glucagon affects glucose metabolism)
- Fasting insulin
- Complete lipid panel
- Liver enzymes (ALT, AST, GGT — critical with glucagon activation)
- Liver fat assessment if NASH suspected
- Thyroid panel
- Kidney function
- Pancreatic enzymes (amylase, lipase)
- DO NOT combine with other GLP-1 agonists
- BPC-157 for GI support during titration
- CJC-1295 / Ipamorelin for muscle preservation
- High protein + resistance training non-negotiable
- Monitor liver enzymes more frequently than with pure GLP-1 compounds
- Limited research-grade availability — pharmaceutical grade only when approved
- Pharmaceutical guidelines when approved
- Research: refrigerate at 2–8°C
- Very limited research-grade availability
- Boehringer Ingelheim pharmaceutical grade preferred
- Do not use claimed survodutide from research vendors
- Store pre-filled pens per manufacturer guidelines
Compounds that complement Survodutide.
Survodutide's dual GLP-1/glucagon mechanism means stacking focuses on muscle preservation, GI support, and non-overlapping fat pathways. Never combine with other GLP-1 or glucagon agonists.
The liver-focused play in a crowded field.
Survodutide isn't going to win the raw weight loss numbers game against tirzepatide or retatrutide. But it might win the NASH game — and that's a massive market with no approved GLP-1 class treatment yet. The glucagon component drives hepatic fat clearance in a way that GIP-based and amylin-based competitors fundamentally cannot. If you have fatty liver disease alongside obesity, survodutide's mechanism is more targeted to your pathology than any approved option. Wait for Phase 3 results and pharmaceutical availability — research-grade survodutide does not meaningfully exist. This is a watch-and-wait compound with enormous potential if the NASH data delivers.
Our free 50-page Protocol Guide includes the complete Metabolic Fat Loss Stack with Survodutide — titration schedules, stacking recommendations, blood work panels, and tracking templates.